BidaskClub upgraded shares of Atrion (NASDAQ:ATRI) from a strong sell rating to a sell rating in a research report sent to investors on Thursday.
Shares of ATRI opened at $631.30 on Thursday. The company has a market cap of $1,168.73, a P/E ratio of 34.14 and a beta of 0.70. Atrion has a 12-month low of $459.50 and a 12-month high of $694.00.
Atrion (NASDAQ:ATRI) last issued its earnings results on Tuesday, February 27th. The medical instruments supplier reported $4.66 earnings per share (EPS) for the quarter. The company had revenue of $34.02 million for the quarter. Atrion had a return on equity of 19.53% and a net margin of 24.96%.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. MetLife Investment Advisors LLC bought a new stake in Atrion during the 4th quarter valued at approximately $390,000. Millennium Management LLC raised its stake in Atrion by 96.0% during the 4th quarter. Millennium Management LLC now owns 784 shares of the medical instruments supplier’s stock valued at $494,000 after purchasing an additional 384 shares during the period. Stone Ridge Asset Management LLC bought a new stake in Atrion during the 4th quarter valued at approximately $271,000. Deutsche Bank AG raised its stake in Atrion by 19.9% during the 4th quarter. Deutsche Bank AG now owns 8,008 shares of the medical instruments supplier’s stock valued at $5,047,000 after purchasing an additional 1,328 shares during the period. Finally, Advisor Group Inc. raised its stake in Atrion by 11.6% during the 4th quarter. Advisor Group Inc. now owns 992 shares of the medical instruments supplier’s stock valued at $625,000 after purchasing an additional 103 shares during the period. 59.05% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION WARNING: This article was first reported by WKRB News and is the sole property of of WKRB News. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.wkrb13.com/2018/04/02/atrion-atri-lifted-to-sell-at-bidaskclub.html.
Atrion Company Profile
Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.